Pfizer Withdraws Sickle Cell Disease Treatment
Pfizer has voluntarily withdrawn its therapy Oxbryta, used for the treatment of sickle cell disease, from all markets where it is approved. The decision is based on the totality of clinical data, which indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use. Pfizer is discontinuing all active voxelotor clinical trials and expanded access programs worldwide. The company's primary concern is for patients who suffer from sickle cell disease, which remains a serious and diffi